Welcome to our dedicated page for Quoin Pharmaceuticals, Ltd. SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quoin Pharmaceuticals Ltd. (QNRX) filings document a State of Israel registrant whose Nasdaq-listed American Depositary Shares each represent 35 ordinary shares. Recent 8-K reports record quarterly and annual financial results, Regulation FD disclosures and material events tied to the company's rare-disease drug-development programs.
The filing record includes disclosures about QRX003 regulatory designations for Netherton Syndrome, QRX009 topical rapamycin delivery technologies, capital-structure matters and board compensation arrangements. These reports also identify the ADS and ordinary-share structure and exchange listing for QNRX securities.
Quoin Pharmaceuticals (QNRX) announced that the FDA granted Orphan Drug Designation (ODD) to its lead candidate QRX003 for treating Netherton Syndrome. This follows ODD from the EMA in May 2025.
ODD provides benefits such as tax credits for qualified clinical testing, waiver or partial payment of FDA application fees, and seven years of U.S. market exclusivity if approved. QRX003 lotion (4%) is in two late‑stage, whole‑body pivotal trials.
Quoin expects enrollment in both pivotal studies to complete in the first quarter of 2026, with top‑line data in the second half of 2026, and an NDA submission planned later in the year.
Quoin Pharmaceuticals (QNRX) closed a private placement, raising approximately $16.6 million in upfront gross proceeds and about $15 million in net proceeds. The financing included ADSs, pre-funded warrants for ADSs, and four series of accompanying warrants, each permitting purchases of up to 2,009,091 ADSs.
The unit price for ADSs and accompanying warrants was $8.25, while pre-funded warrant units were priced at $8.2499. Director Dennis Langer participated, purchasing 15,152 ADSs with accompanying warrants for roughly $128,641 at $8.49. Warrants carry a 4.99% beneficial ownership cap; pre-funded warrants are exercisable at $0.0001 per ADS and allow cashless exercise. If a resale registration is not effective six months after issuance, the ordinary warrants may be exercised cashlessly.
Quoin agreed to file a resale registration within 30 days and target effectiveness within 60 days (or 90 days on full SEC review). The company placed 180‑day financing standstills and obtained 180‑day lock-ups from directors and officers. Potential future gross proceeds from warrant cash exercises total up to about $88.0 million.
Quoin Pharmaceuticals (QNRX) director Dennis Langer reported a purchase of 15,152 ADS on 10/14/2025 at a combined price of $8.49 per ADS in a private placement. Each ADS was purchased together with one Series H, Series I, Series J, and Series K warrant to buy one ADS.
The filing lists warrants for 15,152 ADS each with exercise prices of $9.075 (Series H), $10.3125 (Series I), and $12.375 (Series J and K). The warrants were exercisable immediately, subject to a beneficial ownership cap, and include milestone-based expirations tied to FDA-related events or a Priority Review Voucher sale, or five years from the closing date, whichever occurs earlier as specified for each series.
Following the reported transactions, Langer beneficially owned 15,153 ADS directly. Each ADS represents 35 ordinary shares of the company.
Quoin Pharmaceuticals, Ltd. reported an initial beneficial ownership filing by Sally Bridget Lawlor, identifying her as Chief Financial Officer and a director. The filing reports ownership of 440 ADSs held directly; each ADS represents 35 ordinary shares. The transaction date triggering the filing is 08/18/2025 and the form is signed on 09/08/2025. The report includes a Power of Attorney (Exhibit 24.1).
Quoin Pharmaceuticals Ltd. filed an S-8 registration to register securities related to its employee benefit program. The filing incorporates the companys Form 10-K for the year ended December 31, 2024 and subsequent Form 10-Qs and Form 8-Ks through August 27, 2025. Exhibits include amended articles, a deposit agreement for ADSs, a 2025 Equity Incentive Plan (Exhibit 4.4), legal opinion and accountant consents. The filing supplies standard indemnification and insurance terms for officers and directors under Israeli law.
Quoin Pharmaceuticals reported the separation of an executive under a Separation Agreement that provides three key elements: a cash payment of $433,620 to be delivered in equal bi-weekly installments in lieu of 12 months' notice; a $108,405 bonus for the 2024 financial year to be paid in a lump sum on the one-year anniversary of the Separation Agreement's effective date; and an amendment to outstanding vested non-qualified stock options that extends the post-termination exercise window from 90 days to 1 year and 9 months. The filing is signed by Dr. Michael Myers, Chief Executive Officer, and includes an Inline XBRL cover page reference.
Quoin Pharmaceuticals Ltd. filed a Form S-8 to register securities for its American employee benefit plan. The submission references its Form 10-K for the year ended December 31, 2024, and subsequent Form 10-Qs and multiple Form 8-Ks filed between January and August 2025. The filing includes customary indemnification and insurance provisions for officers and directors, an exhibit list (legal opinion, auditor consent, power of attorney, filing fee table), and is signed by Dr. Michael Myers as CEO and authorized U.S. representative on August 25, 2025.
Quoin Pharmaceuticals director Natalie Ee Mun Leong reported an award of a share option on 08/21/2025 exercisable for 4,105 American Depositary Shares (ADSs) representing underlying ordinary shares. The option’s stated exercise price is $9.07 per ADS. The grant was approved by the Compensation Committee and Board on May 29, 2025 and was subsequently approved by shareholders on August 21, 2025. The option vests over four annual installments: 20% on each of May 29, 2026, 2027 and 2028, and 40% on May 29, 2029.
Anthony James Culverwell, a director of Quoin Pharmaceuticals, Ltd. (QNRX), was granted a stock option on 08/21/2025 covering 13,682 American Depositary Shares (ADSs) with an exercise price of $9.07 per ADS. Each ADS represents 35 ordinary shares, so the option covers the ADS-denominated equivalent of the underlying ordinary shares.
The option was approved by the Compensation Committee and Board on 05/29/2025 and became effective upon shareholder approval on 08/21/2025. The award vests over four annual installments: 20% vesting on each of 05/29/2026, 05/29/2027 and 05/29/2028, and 40% vesting on 05/29/2029. The reported ownership following the grant is 13,682 ADSs, held directly.
Quoin Pharmaceuticals, Ltd. (QNRX) director Dennis Langer was granted a share option to purchase 13,682 ADSs on August 21, 2025, as reported on Form 4 filed August 25, 2025. The option is stated in ADS terms with an exercise price of $9.07 per ADS; each ADS represents 35 ordinary shares. The grant was approved by the Compensation Committee and Board on May 29, 2025, subject to shareholder approval, and shareholders approved it on August 21, 2025. The option vests in four annual installments: 20% on each May 29 of 2026, 2027 and 2028, and 40% on May 29, 2029.